Home Ad Exchange News VivaKi, Publicis Health Media Take Health Care Advertising Programmatic

VivaKi, Publicis Health Media Take Health Care Advertising Programmatic

SHARE:

AODhealthThe confluence of health data and advertising is a privacy-sensitive subject, and marketers have generally been slow to adopt automation in the health care sector.

But two Publicis Groupe agencies are looking to bridge the gap between automation and health care marketing. On Wednesday, VivaKi and Publicis Health Media (PHM) unwrapped their programmatic buying solution for health marketers and publishers, dubbed AOD Health.

Programmatic has lagged in the pharmaceutical and health care sectors, despite swelling ad spend in the industry. eMarketer projects the pharmaceutical industry will spend $1.4 billion on digital media in 2014, and $2.2 billion in 2018.

“Programmatic adoption has been slow in the pharmaceutical and health care sector,” VivaKi’s president of global solutions, Doug Kofoid, told AdExchanger. “So, this is a huge area of growth we’re just now tapping in to.”

Despite apparent hesitance, recent signals from tech companies such as Apple, Google and others suggest that consumer platform companies, at least, are ready to test the waters. Facebook, for instance, is in the early stages of creating online “support communities” that would connect users with similar health interests, Reuters reported late last week.

According to PHM’s director of media, Benjamin Visich, bringing data-driven media buying to the health care sector only requires addressing regulatory and privacy concerns head-on.

“Ensuring that clients are comfortable with this paradigm shift away from repurchasing inventory to leveraging programmatic to purchase qualified, targeted audiences is the main hurdle,” Visich said. “With AOD Health, we’ve ironed out those barriers in terms of the regulatory requirements and the creative requirements as well as some of the ad verification requirements that have been wrapped into this new solution.”

“Our biggest restrictions have actually come from the advertisers and technology vendors,” added Kofoid, “as each takes a slightly different approach to how conservative[ly] they want to be using data to target consumers.”

In terms of the tech, AOD Health rolls together VivaKi’s media-buying platform, Audience On Demand, with PHM’s direct-to-consumer reach. The pairing affords marketers access to both companies’ data, inventory and technology relationships.

According to the press release, “AOD will augment its workflow with steps to identify and adhere to advertiser-specific medical, legal and regulatory policies and preferences for: collecting first-party data through remarketing pixels, targeting strategies such as third-party data prospecting and adhering to industry-specific inventory requirements.”

A handful of clients are already leveraging AOD Health, but the companies declined to identify any.

The Privacy Question

How do VivaKi and PHM plan to overcome privacy concerns that have hindered programmatic adoption in health care?

“We won’t look to leverage PII,” Visich said “A lot of the data we access through partnerships is based on health interest data. This can clearly be differentiated from PII data. But when we couple health interest data with the multitude of sources out there – demographic data, semantic-based data, contextual based data – it runs the gamut of a multitude of data sources without needing to go to that level of PII, which would be truly invasive.”

“But it’s on us to present and voice how we solve for those concerns with our respective clients,” he added, “to make them feel 100% comfortable in using this service prior to launching.”

AOD Health is  in the trial phase, but the aim is to line up an official launch as the companies proceed with their 2015 campaigns.

Must Read

Monopoly Man looks on at the DOJ vs. Google ad tech antitrust trial (comic).

Google And The DOJ Filed Their Proposed Final Judgments In The Ad Tech Case – Here’s What They’re Still Arguing About

Google and the Department of Justice filed the next round of paperwork that will determine what Google’s punishment will look like in the ad tech antitrust case.

T-Mobile Brings Its Mobile Data Exclusively To Vistar To Scale Up DOOH Targeting

Advertisers can now use Vistar to activate both off-the-shelf and custom audiences built on T-Mobile’s first-party location and app data.

Apple Has Far-Reaching Plans To Block Hundreds Of Programmatic Data Companies From iOS

Apple’s WebKit crackdown appears to extend well beyond The Trade Desk, putting hundreds of ad tech, data and identity vendors on a mysterious, dynamically updated block list.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
Josh Reed, Zoom's VP of brand and content, speaking at AdExchanger's Programmatic IO event in New York City (September 28, 2006)

Zoom’s Marketing Challenge Is That It’s Too Well Known For Its Own Good

Zoom has 99% unaided brand awareness, which sounds great on paper. But there’s a catch: Most people still think it’s just a video-call app.

Why Agencies Think They Shouldn’t Own Agentic AI Tools Or The Data Used To Build Them

Agencies are differentiating their tech stacks by building custom agentic AI tools for their clients. And they’re rethinking owning those AI tools – particularly since licensing them creates new revenue streams.

Programmatic IO: Insurers Are Building Ad Tech’s AI Accountability Layer

Agencies and marketers discussed the future of AI governance at AdExchanger’s Programmatic IO NYC this week. The main takeaway? Expect insurers to play an increasingly important role in managing AI compliance.